<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04775680</url>
  </required_header>
  <id_info>
    <org_study_id>ADG106-1008</org_study_id>
    <nct_id>NCT04775680</nct_id>
  </id_info>
  <brief_title>Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma</brief_title>
  <official_title>A Multicenter, Open-Label, Phase Ib/II Study of ADG106 in Combination With PD-1 Antibody in Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adagene (Suzhou) Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adagene Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Multicenter, Open-Label, Phase Ib/II Study of ADG106 in Combination with PD-1&#xD;
      Antibody in Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma.&#xD;
&#xD;
      The primary objective of Phase Ib: To evaluate the maximum tolerated dosage (MTD) of ADG106&#xD;
      in combination with PD-1 antibody in advanced solid tumors and relapsed/refractory&#xD;
      non-Hodgkin lymphoma, and to determine the recommended phase II clinical studies dosage&#xD;
      (RP2D).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing dosage limiting toxicity (DLT) in the first treatment cycle of the combination of ADG106 and PD-1 antibody.</measure>
    <time_frame>From first dose of ADG106 and PD-1 antibody (Week 1 Day 1) until 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR) of the combination of ADG106 and PD-1 antibody in advanced solid tumors and relapsed/refractory non-hodgkin lymphoma</measure>
    <time_frame>From baseline to measured progressive disease (up to 24 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Type of adverse event, incidence, grade (according to NCI CTCAE V 5.0 classification), onset time, and relationship to study treatment</measure>
    <time_frame>From the first dose of ADG106 and PD-1 antibody (Week 1 Day 1) to 28 days post last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the time concentration curve(AUC) from time zero to infinity (AUC0-inf))</measure>
    <time_frame>From the first dose of ADG106 and PD-1 antibody (Cycle 1 Day 1,each cycle is 21 days) until the last dose (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum (peak) plasma concentration (Cmax)</measure>
    <time_frame>From the first dose of ADG106 and PD-1 antibody (Cycle 1 Day 1,each cycle is 21 days) until the last dose (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum(peak) plasma concentration Tmax</measure>
    <time_frame>From the first dose of ADG106 and PD-1 antibody (Cycle 1 Day 1,each cycle is 21 days) until the last dose (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Through plasma concentration(Cthrough)</measure>
    <time_frame>From the first dose of ADG106 and PD-1 antibody (Cycle 1 Day 1,each cycle is 21 days) until the last dose (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibody levels of ADG106 and PD-1 antibody</measure>
    <time_frame>From the first dose of ADG106 and PD-1 antibody (Cycle 1 Day 1,each cycle is 21 days) until the last dose (up to 2 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Non Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>ADG106 combined with PD-1 antibody Dose Escalation Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ADG106 combined with anti PD-1 antibody Dose Escalation Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ADG106 combined with anti PD-1 antibody Expansion Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ADG106 injection</intervention_name>
    <description>ADG106 injection, intravenous infusion, is administered as body weight every 3 weeks for 21 days as a cycle</description>
    <arm_group_label>ADG106 combined with PD-1 antibody Dose Escalation Level 1</arm_group_label>
    <arm_group_label>ADG106 combined with anti PD-1 antibody Dose Escalation Level 2</arm_group_label>
    <arm_group_label>ADG106 combined with anti PD-1 antibody Expansion Phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PD-1 antibody injection</intervention_name>
    <description>PD-1 antibody injection is administered as an intravenous infusion and at a dose of 240mg every 3 weeks for 21 days as a cycle</description>
    <arm_group_label>ADG106 combined with PD-1 antibody Dose Escalation Level 1</arm_group_label>
    <arm_group_label>ADG106 combined with anti PD-1 antibody Dose Escalation Level 2</arm_group_label>
    <arm_group_label>ADG106 combined with anti PD-1 antibody Expansion Phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with advanced solid tumors or relapses/refractory non-Hodgkin's lymphoma&#xD;
             confirmed by histology or cytology&#xD;
&#xD;
          -  Has at least one measurable lesion (solid tumor according to RECIST v1.1 criteria,&#xD;
             non-Hodgkin's lymphoma according to Lugnao criteria)&#xD;
&#xD;
          -  ECOG score of 0 or 1;&#xD;
&#xD;
          -  Expected survival time â‰¥ 3 months (at the discretion of the investigator);&#xD;
&#xD;
          -  Adequate organ and bone marrow function;&#xD;
&#xD;
          -  Voluntarily sign the informed consent form;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has central nervous system primary malignant tumor, active epileptic seizure, spinal&#xD;
             cord compression or carcinomatous meningitis&#xD;
&#xD;
          -  The previous anti-tumor treatment has not passed the prescribed washout period&#xD;
&#xD;
          -  HIV antibody is positive, or with other acquired/congenital immunodeficiency disease,&#xD;
             or with history of organ transplantation;&#xD;
&#xD;
          -  Active hepatitis B or hepatitis C virus (HCV) antibody was positive;&#xD;
&#xD;
          -  Patients who are pregnant or lactating;&#xD;
&#xD;
          -  Known or suspected hypersensitivity to the study drug or its pharmaceutical excipients&#xD;
             (including mono-hydrate citric acid, sodium di-hydrate citric acid, mannitol,&#xD;
             polysorbate, arginine, succinic acid);&#xD;
&#xD;
          -  Any active autoimmune disease, or known history of autoimmune disease, or syndrome&#xD;
             requiring systemic steroids or immunosuppressive medications (other than controlled&#xD;
             thyroid disease with alternative therapy/non-immunosuppressive therapy);&#xD;
&#xD;
          -  Participation in another therapeutic or interventional clinical study in the meantime;&#xD;
&#xD;
          -  Other circumstances where the investigator considers it is not appropriate to&#xD;
             participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaohong She</last_name>
    <phone>1-408-838-9296</phone>
    <email>kristine_she@adagene.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hua Gong</last_name>
    <phone>1-858-695-4033</phone>
    <email>hua_gong@adagene.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Zhang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 16, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumor and Non Hodgkin Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

